Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Not yet recruiting 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 224Rectal Neoplasms 124Colonic Neoplasms 120Stomach Neoplasms 60Pancreatic Neoplasms 58Neoplasm Metastasis 48Lymphoma 39Precursor Cell Lymphoblastic Leukemia-Lymphoma 35Leukemia 32Esophageal Neoplasms 32Neoplasms 31Burkitt Lymphoma 18Adenocarcinoma Of Esophagus 17Adenocarcinoma 17Carcinoma, Hepatocellular 13Lymphoma, Non-Hodgkin 12Lymphoma, Large B-Cell, Diffuse 12Unspecified Adult Solid Tumor, Protocol Specific 11Biliary Tract Neoplasms 11Lymphoma, Mantle-Cell 10Gallbladder Neoplasms 10Liver Neoplasms 9Osteosarcoma 8Lymphoma, Large-Cell, Immunoblastic 8Gastrointestinal Neoplasms 8Bile Duct Neoplasms 8Lymphoma, Follicular 7Dendritic Cell Sarcoma, Interdigitating 7Cholangiocarcinoma 7Leukemia, Myeloid, Acute 6

Interventions

Fluorouracil 2Docetaxel 2thymoglobulin 1temsirolimus 1sargramostim 1pirarubicin 1pembrolizumab 1pazopanib 1fludarabine phosphate 1fludarabine 1cc-486 1X-Rays 1Whole-Body Irradiation 1Trastuzumab 1Tacrolimus 1Surveys and Questionnaires 1Rituximab 1Radiotherapy 1Proctectomy 1Pemetrexed 1Oxaliplatin 1Mycophenolic Acid 1Monatide (IMS 3015) 1Metformin 1Melphalan 1Leucovorin 1Granulocyte-Macrophage Colony-Stimulating Factor 1Epirubicin 1Drug Therapy 1Diphenhydramine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Pathologic Complete Response × Leucovorin × Clear all
NCT01216644 2019-06-19

5-FU, Leucovorin, Oxaliplatin and Docetaxel (FLOT) Versus Epirubicin, Cisplatin and 5-FU (ECF) in Patients With Locally Advanced, Resectable Gastric Cancer

Krankenhaus Nordwest

Phase 2/3 Completed
716 enrolled
Gastrointestinal

Pathologic Complete Response, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡